Answers are grounded in this paper and cite their sources.
A funny sign was posted on social media recently—the image of a Dairy Queen sign with the block letter message below “Ruining Your New Year's Resolution Since 1962.” So true. That day in church, the minister brought up New Year’s resolutions, pointing out that their history goes back some 4000 years to the Babylonians in the era of the new year starting in mid-March. Resolutions involved affirming the reigning king and making promises to the gods. The Romans then moved the calendar start back to January in 46 B.C.—the month named for the god Janus, who was a spirit inhabiting doorways and arches. The significance of Janus was the idea of looking backward into the previous year and ahead to the future. Despite the religious beginnings, New Year’s resolutions have migrated to a more secular tradition with more themes of self-improvement. You can read more on this from an article on the History Chanel authored by Sarah Pruitt.1 For JUOP going into the new year, we finished our second full year with 12 new issues published and received 170 new submissions. We added several new experts to our editorial board. Going into our third year, we hope to pursue PubMed Central indexing and to expand our submission rate and publication size further toward 200 articles per year. In our issue editorials, we have highlighted our 6 key methodologies, and in this article, we highlight the final format of a retrospective study. Our board members Henry Woo and Bernardo Rocco led this writing with their colleague Maria Chiara Sighinolfi, MD. RETROSPECTIVE STUDY OPPORTUNITIES: HARNESSING THE POWER OF PAST DATA In the evolving landscape of medical research, retrospective studies remain a cornerstone, offering unique insights derived from previously collected data. By leveraging this approach, researchers can illuminate patterns, evaluate outcomes, and generate hypotheses that drive clinical innovation. Retrospective studies, despite their inherent limitations, present a wealth of opportunities when strategically designed and thoughtfully interpreted. ADVANTAGES OF RETROSPECTIVE STUDIES Retrospective studies use existing data, allowing for swift analyses without the logistical challenges of prospective trials. These studies are particularly advantageous for rare conditions or long-term outcomes, where collecting new data might be infeasible. In addition, they are cost-effective, often requiring fewer resources compared with prospective designs. By focusing on real-world evidence, retrospective studies bridge the gap between controlled experimental settings and everyday clinical practice, thereby enhancing the external validity of findings. One notable example is their application in rare diseases, where prospective trials often face recruitment challenges. Recently, Qian et al2 retrospectively collected data on open retroperitoneal nodal dissection (RPLND) for testicular cancer. The recruitment of patients in the field is generally poor, and the retrospective design allowed for high-volume collection of cases granting the comparison between the primary and postchemo setting, otherwise not feasible. The authors indicate favorable perioperative outcomes within the open surgery setting. While long-term outcome data are necessary to properly select patients for robotic RPLND, open RPLND, when performed by experienced surgeons, continues to enhance its results and remains the standard approach in current practice.2 Another example of rare condition is urachal carcinoma. Kirisawa et al3 addressed the topic from a retrospective revision of the Japan National Cancer Registry. Within a database of 51 patients, the authors found that the involvement of perivesical fat and tumor grade were significant predictors of poor overall survival. Retrospective analyses have uncovered critical insights into disease progression and response to treatments, guiding both clinical decisions and the design of future studies. The collection of retrospective data sets is the very base of multivariate analysis to guide outcome prediction through the development of models. For example, from the Surveillance, Epidemiology, and End Results Program database, Li et al4 developed a prognostic nomogram for older patients with urothelial carcinoma. A model predicting outcomes is valuable for both physician and patients and may guide decision-making and expectations. Similarly, in long-term outcomes research, retrospective designs have proven invaluable in assessing the durability of interventions, such as diagnostic procedures and pharmacological therapies, over extended periods. For example, the usefulness of prostate specific membrane antigen-positron emission tomography (PSMA-PET) was recently addressed over a consecutive retrospective series of 1220 patients.5 From this data set, PSMA-PET provided a 13.2% absolute increase in the detection of nodal lesion and 24% absolute increase in metastatic lesions compared with MRI; however, the impact of stage migration still remains unaddressed. Similarly, retrospective studies may assess the value of screening interventions over time. By using data from the Military Health System Data Repository, the impact of the COVID-19 pandemic on the slowdown of prostate cancer screening was definitely defined, finding an overwhelming 73% reduction in PSA assessment in the early pandemic era.6 In urology, retrospective studies have provided pivotal data on the effectiveness of new minimally invasive technologies, allowing for feasibility and safety assessments. For example, the introduction of new robotic systems was reported by Rocco et al7 within a case series including Hugo RAS and Versius. The experience defined the safety of those new platforms for radical prostatectomy and highlighted the issues—that is, malfunctioning—typical of each robotic systems. CHALLENGES AND MITIGATION STRATEGIES Although valuable, retrospective studies are not without challenges. Issues such as incomplete data, selection bias, and confounding variables can compromise their reliability. To mitigate these limitations, researchers must adopt robust statistical techniques, such as propensity score matching (PSM) or multivariate analyses, to adjust for confounding factors. Houjaij et al8 recently reported on the comparison between partial and radical nephrectomy in terms of complications. From a database including 24,830 patients who underwent kidney surgery, a PSM was performed to adjust for confounding variables. In the field, the covariates used for PSM included age, preoperative hematocrit, diabetes, chronic kidney disease, presence of distant metastasis, hypertension, congestive heart failure, chronic obstructive pulmonary disease, chronic use of steroids, weight loss > 10%, ascites, bleeding disorders, and American Society of Anesthesiologists physical status. With this mitigating strategy, complications seemed most frequent after radical than after partial nephrectomy. In addition, clear documentation of methodologies and transparent reporting of potential biases are essential for ensuring credibility. Innovative approaches are also emerging to address these challenges. The integration of machine learning algorithms, for instance, allows researchers to handle large data sets efficiently, identifying patterns that might otherwise be obscured by traditional methods. Advanced data imputation techniques are helping to fill gaps in incomplete data sets, ensuring more comprehensive analyses. In urology, the use of these technologies has facilitated the analysis of vast biobanking repositories, enabling researchers to extract meaningful insights about biomarkers linked to urological malignancies and treatment responses. APPLICATIONS ACROSS MEDICAL DISCIPLINES The versatility of retrospective studies extends across numerous fields. In oncology, for instance, retrospective analyses have been instrumental in identifying prognostic factors and refining treatment protocols. For example, large-scale retrospective reviews of cancer registries have elucidated the impact of various therapies on survival rates, paving the way for more personalized treatment approaches. Retrospective analysis may retrieve data from small subgroups of patients, that is, those who are misclassified after assessing long-term outcomes of impact of misclassification of neoadjuvant chemotherapy responders was addressed through a retrospective revision of a prospectively maintained database. Similarly, in cardiology, retrospective data have shed light on the long-term safety and efficacy of interventions such as coronary stenting and valve replacement. In urology, retrospective studies have elucidated long-term outcomes of surgical interventions and the comparative effectiveness of various therapies. These studies have also been crucial in evaluating the impact of technological advancements, such as robotic surgery, on patient outcomes. Furthermore, the integration of retrospective data with modern technologies, such as artificial intelligence, has unlocked new dimensions of analysis, enabling pattern recognition and predictive modeling at unprecedented scales. Biobanking initiatives in urology, which store patient-derived biological samples alongside clinical data, represent a powerful synergy with retrospective research. These repositories have catalyzed discoveries in prostate cancer biomarkers, advancing risk stratification and therapeutic personalization. ETHICAL CONSIDERATIONS Given the reliance on preexisting data, retrospective studies pose unique ethical considerations. Ensuring patient confidentiality and adhering to data governance regulations are paramount. Institutional review boards play a critical role in overseeing these studies, balancing the benefits of research against the need to protect individual rights. Transparency in data handling and ensuring informed consent where applicable are vital components of ethical retrospective research. Furthermore, as data-sharing initiatives gain traction, researchers must navigate complex ethical landscapes to ensure that data usage aligns with both regulatory standards and public expectations. This is particularly important in the era of big data, where the aggregation of data sets from multiple sources can significantly amplify both the potential benefits and risks associated with research. Biobanking efforts, in particular, demand rigorous ethical oversight to ensure that samples and associated data are used responsibly and in line with donor consent. THE FUTURE OF RETROSPECTIVE RESEARCH As electronic health records and large-scale databases continue to expand, the potential for retrospective studies grows exponentially. By incorporating advanced analytics and cross-disciplinary collaborations, researchers can maximize the utility of historical data. Retrospective studies are poised to complement prospective trials, providing a comprehensive view of clinical phenomena and accelerating the translation of research into practice. The integration of retrospective data with cutting-edge technologies, such as natural language processing and blockchain, promises to further enhance the scope and reliability of these studies. Natural language processing can extract valuable insights from unstructured data sources, such as clinical notes, while blockchain ensures data integrity and security, fostering greater trust in research outcomes. These innovations highlight the dynamic and evolving nature of retrospective research, ensuring its continued relevance in the scientific community. In urology, the convergence of retrospective analyses and biobanking is likely to yield transformative advances, particularly in the domains of genetic profiling, immunotherapy, and precision medicine. CONCLUSIONS Retrospective studies are a powerful tool in the research arsenal, offering insights that might otherwise remain obscured. While challenges persist, meticulous design and innovative methodologies can unlock their full potential. The medical community must continue to embrace retrospective research as a vital component of evidence generation, ensuring that lessons from the past inform the advancements of the future. The integration of retrospective analyses with prospective research paradigms can create a synergistic model, where the strengths of both approaches are leveraged to provide a more holistic understanding of clinical questions. By valuing and investing in retrospective research, we can build a robust foundation for medical progress. In urology, this approach is particularly compelling because the wealth of data housed in biobanks offers unparalleled opportunities to unravel complex disease mechanisms and refine therapeutic strategies. Ensuring that the knowledge gained from past data continues to shape and improve patient care for generations to come remains a shared responsibility and a vital goal for the global research community. DECEMBER JUOP ARTICLES Given the focus on retrospective studies, we will abbreviate the article issues for this month into key bullet points: Reviews: Henderson et al9 present a comprehensive, narrative review on somatic and germline testing in prostate cancer. This work includes several focus areas such as guidelines statements, patient selection, care delivery, test ordering options, cost and payer coverage, patient education, and more. Clinical trials: Treacy et al10 present an IRB-approved pilot trial of multiphoton microscopy to assess bladder cancer in cold cup biopsies. They found 80% sensitivity for resection depth and suggest this method be further studied toward the goal of avoiding unnecessary second procedures. Health services research: Smith et al11 looked at the topic of preventive pharmacological therapy for kidney stones. They used claims data from the Optum Clinformatics Data Mart database. They found that follow-up urine testing after prevention could improve medication adherence. Retrospective study: Sood et al12 looked at the practice of using pT0 (pathologic no primary tumor) status at radical cystectomy after chemotherapy for bladder cancer. It is a multilayer set of ideas tested, but a key point is the study of biopsy-proven node-positive patients. There was a high degree of discordance between local and nodal response to chemotherapy. They suggest that nodal response may be more valuable because some patients are pT0 from the transurethral resection of bladder tumor efforts. Rare conditions: Schott et al13 describe a case of ureteroduodenal fistula from an impacted stone. The case discusses etiology, presentation, and the key imaging and endoscopic images. PEOPLE, PLACES, AND THINGS Because December is mostly a holiday season, I did not have any academic events to feature. In Houston, we have mostly mild winter weather and a trip to the local zoo can be fun, rather than a summer visit in 100° heat. It got me thinking that there are several different environments to practice animal photography—aquariums, zoos, wildlife parks, and the actual wild. Depending on how you frame a picture, it may be difficult to tell the difference. Figures 1-4 show some highlights of my visits to these 4 different areas. Enjoy and see you next month.Figure 1.: From the aquarium. A, The sea nettle floats with the current and moves with rhythmic contractions. They are food to many species such as sea turtles, fish, and crabs. To humans, they have a powerful sting from their tentacles. B, Sea turtles—great swimmers; a bit slow on land. As swimmers, they can cross oceans and dive up to 3000 feet.Figure 2.: From the wild. A, This bald eagle is from SE Alaska near Baranof Island. B, An SE Alaska humpback whale breaches in Frederick Sound. Scientists say they do this for communication, play, or to show off, but not sure which. This one jumped constantly for 15 minutes in front of us, so will go with show off. C, From Yellowstone National Park—the bison can weigh up to 2000 pounds and run 35 miles per hour. In the winter, they are often found near thermal areas that keep grass available through the long winter season. D, The brown bear of SE Alaska. In September, the salmon start to spawn and the bears eagerly await along the shorelines. They are often called apex predators.Figure 3.: The preserve. A, This lynx resides at Steve Kroschel’s wildlife center in Haines, Alaska. B, The snowy owl—also from Steve Kroschel’s wildlife center in Haines, Alaska. C, The white rhino—from a nature preserve near Cape Town, South Africa.Figure 4.: The zoo. A, The Chilean flamingo—naturally a more white feather but gains its pink from the food it eats, with its upside-down filtering method. B, The radiated tortoise gets its name from the high dome with yellow lines radiating from the center. As a urologist, I want to come up with some good jokes on how this tortoise compares with the surgical tortoise. C, The lions—from their natural looking habitat. Fortunately this argument resolved quickly as they do not have a good way to get away from each other. D, This orangutan from the Houston Zoo has no problem posing for pictures.
No takes yet. Share an insight, caveat, or question.
Rocco et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: